See more : TruScreen Group Limited (TRU.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Calyxt, Inc. (CLXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calyxt, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Epsilon Net S.A. (EPSIL.AT) Income Statement Analysis – Financial Results
- China State Construction International Holdings Limited (CCOHF) Income Statement Analysis – Financial Results
- Academies Australasia Group Limited (AKG.AX) Income Statement Analysis – Financial Results
- Triumph Gold Corp. (TIGCF) Income Statement Analysis – Financial Results
- Maiyue Technology Ltd (2501.HK) Income Statement Analysis – Financial Results
Calyxt, Inc. (CLXT)
About Calyxt, Inc.
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 0.00 | 28.56M | 35.13M | 9.28M | 0.00 | 0.00 | 200.00K | 751.00K |
| Gross Profit | 157.00K | -2.57M | -11.28M | -1.98M | 236.00K | 508.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 100.00% | -9.89% | -47.28% | -27.19% | 100.00% | 100.00% | 49.87% | 40.96% |
| Research & Development | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 5.57M | 45.00K | 252.00K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 1.53M | 810.00K | 3.24M | 3.21M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -22.37M | -28.52M | -40.59M | -36.47M | -28.12M | -25.79M | -11.74M | -5.48M |
| EBITDA Ratio | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,830.08% | -5,005.51% | -2,941.35% | -430.90% |
| Operating Income | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -7.09M | -114.00K | 1.56M | 1.49M | 1.48M | -190.00K | 28.00K | 186.00K |
| Net Income | -9.80M | -29.09M | -46.40M | -41.10M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -6,243.95% | -111.92% | -194.54% | -563.35% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| EPS Diluted | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| Weighted Avg Shares Out | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
| Weighted Avg Shares Out (Dil) | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
The Promise And Fear Of Gene Editing
It’s easy to talk about gene editing and genetic modification in terms that sound like science fiction. But as much as that may drive clicks for media sensationalists, it does more harm than good for those who really want to...
Analysts Expect Calyxt Inc (NASDAQ:CLXT) to Post -$0.33 Earnings Per Share
Wall Street brokerages predict that Calyxt Inc (NASDAQ:CLXT) will announce ($0.33) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Calyxt’s earnings. Calyxt posted earnings per share of ($0.23) during...
Calyxt Inc (NASDAQ:CLXT) Stake Raised by State Street Corp
State Street Corp increased its holdings in Calyxt Inc (NASDAQ:CLXT) by 9.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,450 shares of the...
Calyxt (NASDAQ:CLXT) Downgraded by Zacks Investment Research
Zacks Investment Research cut shares of Calyxt (NASDAQ:CLXT) from a hold rating to a sell rating in a report issued on Thursday, Zacks.com reports. According to Zacks, “Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. It researches and develops...
Calyxt Inc (NASDAQ:CLXT) Shares Acquired by KBC Group NV
KBC Group NV increased its holdings in Calyxt Inc (NASDAQ:CLXT) by 3,558.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,000 shares of the company’s stock after acquiring...
Calyxt (NASDAQ:CLXT) Earns Buy Rating from National Securities
National Securities restated their buy rating on shares of Calyxt (NASDAQ:CLXT) in a research note published on Friday, AnalystRatings.com reports. The brokerage currently has a $16.00 price target on the stock. Several other research analysts have also recently issued reports...
Calyxt (NASDAQ:CLXT) Downgraded to Equal Weight at Wells Fargo & Co
Wells Fargo & Co downgraded shares of Calyxt (NASDAQ:CLXT) from an overweight rating to an equal weight rating in a research note published on Friday, BenzingaRatingsTable reports. The brokerage currently has $6.00 target price on the stock, down from their...
Fmr LLC Has $27.21 Million Stock Holdings in Calyxt Inc (NASDAQ:CLXT)
Fmr LLC trimmed its stake in shares of Calyxt Inc (NASDAQ:CLXT) by 19.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,881,700 shares...
Calyxt (NASDAQ:CLXT) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Calyxt (NASDAQ:CLXT) from a sell rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. It...
Calyxt (CLXT) Gets a Buy Rating from National Securities Corp
In a report released today, Ben Klieve from National Securities Corp maintained a Buy rating on Calyxt (CLXT), with a price target of $16.00. The
Source: https://incomestatements.info
Category: Stock Reports